Jazz Pharmaceuticals plc 8K

Jazz Pharmaceuticals, Inc. agreed to acquire Actio Biosciences, Inc. through a merger of its merger subsidiary Knight Acquisition Corp. into Actio Biosciences under an Agreement and Plan of Merger dated August 10, 2026.

On August 10, 2026, Jazz Pharmaceuticals, Inc., a Delaware corporation, entered into an Agreement and Plan of Merger with Knight Acquisition Corp., a Delaware corporation formed as a merger subsidiary, and Actio Biosciences, Inc., a Delaware corporation, pursuant to which Knight Acquisition Corp. will merge with and into Actio Biosciences, with Actio surviving as a subsidiary of Jazz Pharmaceuticals, Inc.; the agreement also provides for the treatment of Actio’s shares, equity awards, warrants and notes, the possibility of contingent consideration, the appointment of Shareholder Representative Services LLC as securityholders’ agent, and the limited involvement of Jazz Pharmaceuticals Public Limited Company for specified sections, with certain immaterial confidential terms redacted under Regulation S-K Item 601(b).

Filing Facts

CIK

1232524

Ticker

JAZZ

Form

8K

Source Type

fda

Accession

0001193125-26-342667

Alert Tier

8